Akebia Therapeutics, Inc.
AKBA
$2.06
$0.168.42%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -69.41M | -45.99M | -40.44M | -43.03M | -51.93M |
| Total Depreciation and Amortization | 41.70M | 41.78M | 41.82M | 41.81M | 41.85M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 26.73M | 18.36M | 8.86M | 8.64M | 7.42M |
| Change in Net Operating Assets | -39.68M | -52.65M | -49.20M | -32.70M | -20.73M |
| Cash from Operations | -40.66M | -38.50M | -38.97M | -25.28M | -23.38M |
| Capital Expenditure | -33.00K | -31.00K | -29.00K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -33.00K | -31.00K | -29.00K | -- | -- |
| Total Debt Issued | 45.00M | 45.00M | 45.00M | 37.00M | -- |
| Total Debt Repaid | -37.10M | -45.10M | -45.10M | -52.73M | -32.00M |
| Issuance of Common Stock | 43.03M | 27.42M | 25.73M | 25.71M | 6.79M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.27M | -1.27M | -750.00K | -750.00K | -- |
| Cash from Financing | 49.66M | 26.05M | 24.88M | 9.24M | -25.21M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.97M | -12.48M | -14.13M | -16.04M | -48.59M |